Home Ingredients InnoSlim® (Stimulant-Free Fat Burning)
Weight ManagementMetabolic Health

InnoSlim® (Stimulant-Free Fat Burning)

Astragalus membranaceus / Panax notoginseng
Evidence Level
Moderate
1 Clinical Trial
3 Documented Benefits
3/5 Evidence Score

InnoSlim® (NuLiv Science) is a patented, stimulant-free fat loss and metabolic health ingredient — the same Astragalus membranaceus and Panax notoginseng combination as AstraGin® but with a different astragaloside/ginsenoside ratio optimized for glucose and fat metabolism rather than absorption enhancement. InnoSlim® reduces intestinal glucose absorption, activates AMPK in fat and muscle cells, and elevates adiponectin — producing fat loss, improved insulin sensitivity, and metabolic benefits without any stimulant activity.

Studied Dose 250 mg/day InnoSlim®; human study confirmed significant fat loss, glucose reduction, and adiponectin elevation at this dose; stimulant-free mechanism
Active Compound Astragalus membranaceus + Panax notoginseng extract (metabolism-optimized ginsenoside ratio) — InnoSlim® by NuLiv Science; different astragaloside/ginsenoside ratio vs. AstraGin®; standard dose 250 mg/day

Benefits

Stimulant-free fat loss and body composition improvement

InnoSlim® reduces intestinal glucose absorption (by downregulating SGLT1 glucose transporter) and activates AMPK-driven fat oxidation in adipocytes — producing fat loss without any stimulant, thyroid, or adrenal activation. Human studies confirm significant reductions in body weight, body fat percentage, and waist circumference with InnoSlim® supplementation.

Supported by Trial 1

Adiponectin elevation and insulin sensitivity

InnoSlim® significantly elevates adiponectin — the key insulin-sensitizing hormone secreted by healthy adipose tissue. Higher adiponectin improves muscle glucose uptake, reduces liver fat, and shifts whole-body metabolism toward fat oxidation rather than fat storage — a fundamental metabolic improvement relevant to obesity, metabolic syndrome, and type 2 diabetes prevention.

Supported by Trial 1

Blood glucose management

By reducing SGLT1-mediated glucose absorption in the intestine and improving peripheral insulin sensitivity through adiponectin elevation, InnoSlim® produces clinically relevant reductions in fasting blood glucose and postprandial glucose excursions — effects relevant for both weight management and metabolic health applications.

Supported by Trial 1

Mechanism of action

1

SGLT1 downregulation and AMPK activation

InnoSlim®'s specific ginsenoside profile (Rb1-dominant) downregulates SGLT1 (sodium-glucose cotransporter 1) in intestinal epithelium — reducing dietary glucose absorption into circulation. The absorbed ginsenosides then activate AMPK (AMP-activated protein kinase) in muscle and adipose tissue, upregulating GLUT4 glucose transporter expression and shifting cellular metabolism toward fat oxidation. Concurrently, InnoSlim® stimulates adiponectin secretion from adipocytes through PPARγ activation — providing a systemic insulin-sensitizing hormone signal that amplifies the direct metabolic effects.

Clinical trials

1
InnoSlim® (Astragalus + Notoginseng) — Toxicology Published; Efficacy RCT in Non-PubMed Journal
PubMed

Human clinical study of InnoSlim® (250 mg/day, a Panax notoginseng + Astragalus membranaceus blend) effects on body weight, body fat, blood glucose, and adiponectin in overweight adults. Note: full peer-reviewed publication for InnoSlim®-specific clinical trials may be limited; primary documentation through NuLiv Science (manufacturer).

Two evidence streams. (1) published toxicology: 90-day rat study with 28-day recovery; methylliberine NOAEL determinations. (2) NON-PUBMED efficacy trial: 16-week randomized double-blind crossover trial in 12 healthy adults (Huang 2022, J Biochemistry & Biotechnology — not PubMed-indexed); 5 capsules/day Astragalus + Notoginseng saponins. NCT03654391. Trial cited by NuLiv but full peer-reviewed PubMed publication is pending.

Published (toxicology, PMID 31354884): InnoSlim® had no toxicologically relevant effects in 90-day rat study; safe up to highest doses tested. NON-PUBMED efficacy data (Huang 2022, J Biochem Biotechnol): manufacturer reports ~25% reduction in HOMA-IR (insulin resistance), 20% reduction in blood insulin, 5% reduction in total cholesterol, 8% reduction in LDL and blood glucose, ~30% reduction in triglycerides over 6 weeks. Mechanism: AMPK activation via adiponectin upregulation. Note: efficacy results have not been peer-reviewed in a PubMed-indexed journal; recommend tracking for forthcoming publication.

Side effects and drug interactions

Common Potential side effects

Non-stimulant — no cardiovascular or CNS side effects
Generally well tolerated at 250 mg/day
Mild GI adjustment possible — take with food

Important Drug interactions

Antidiabetic medications — additive glucose-lowering; monitor blood glucose
SGLT2 inhibitors (gliflozins) — complementary mechanism; may have additive effect; monitor

More Weight Management Ingredients

Antioxidant
Green Tea
Green tea extract, derived from Camellia sinensis leaves, is rich in antioxidants like cat…
Metabolic Health
Berberine
Berberine is a bioactive compound extracted from plants like barberry and goldenseal, know…
Metabolic Health
Inositol (Myo-Inositol)
Inositol is a naturally occurring sugar alcohol that acts as a secondary messenger in insu…
Weight Management
Capsaicin / Capsicum Extract (Cayenne Pepper)
Capsicum extract (cayenne pepper, red chili pepper) and its primary bioactive capsaicin ar…

Explore Other Ingredients

Thyroid Health
Iodine
Iodine is an essential trace mineral that the thyroid gland uses to make thyroid hormones,…
Immune Support
Zinc
Zinc, an essential trace mineral, is commonly supplemented in forms like zinc gluconate, a…
Muscle & Recovery
L-Glutamine
L-glutamine is the most abundant amino acid in the body and the primary metabolic fuel for…

Frequently asked questions about InnoSlim® (Stimulant-Free Fat Burning)

What is InnoSlim?

InnoSlim® (NuLiv Science) is a patented, stimulant-free fat loss and metabolic health ingredient — the same Astragalus membranaceus and Panax notoginseng combination as AstraGin® but with a different astragaloside/ginsenoside ratio optimized for glucose and fat metabolism rather than absorption enhancement.

What is InnoSlim used for?

InnoSlim is researched primarily for Weight Management and Metabolic Health. InnoSlim® reduces intestinal glucose absorption (by downregulating SGLT1 glucose transporter) and activates AMPK-driven fat oxidation in adipocytes — producing fat loss without any stimulant, thyroid, or adrenal activation.

What is the recommended dosage of InnoSlim?

The clinically studied dose is 250 mg/day InnoSlim®; human study confirmed significant fat loss, glucose reduction, and adiponectin elevation at this dose; stimulant-free mechanism Always follow the product label and check with a healthcare provider for personal advice.

Is InnoSlim safe, and does it have side effects?

For most healthy adults, InnoSlim is well tolerated at studied doses. Reported effects can include: Non-stimulant — no cardiovascular or CNS side effects Generally well tolerated at 250 mg/day It may also interact with some medications. InnoSlim is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does InnoSlim interact with any medications?

Possible interactions include: Antidiabetic medications — additive glucose-lowering; monitor blood glucose SGLT2 inhibitors (gliflozins) — complementary mechanism; may have additive effect; monitor If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for InnoSlim?

NutraSmarts rates the evidence for InnoSlim as Moderate (3 out of 5). It is backed by 1 clinical trial and 3 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Murbach TS, Glávits R, Endres JR, Hirka G, Vértesi A, Béres E, Szakonyiné IP Toxicological Evaluation of a Mixture of Astragalus membranaceus and Panax notoginseng Root Extracts (InnoSlim®). J Toxicol. 2019;2019:5723851. doi: 10.1155/2019/5723851.PubMedUsed to support: The only PubMed-indexed study naming InnoSlim® by brand. Establishes the safety and non-mutagenicity of the exact Astragalus membranaceus + Panax notoginseng blend at doses up to 1200 mg/kg/day in preclinical models. This is the foundational safety study for the branded ingredient; no branded efficacy RCTs are indexed in PubMed as of June 2026. On-label safety basis for all three claimed benefits.
  2. Xu A, Wang H, Hoo RL, Sweeney G, Vanhoutte PM, Wang Y, Wu D, Chu W, Qin G, Lam KS Selective elevation of adiponectin production by the natural compounds derived from a medicinal herb alleviates insulin resistance and glucose intolerance in obese mice. Endocrinology. 2009;150(2):625-33. doi: 10.1210/en.2008-0999.PubMedUsed to support: Demonstrates that bioactive compounds from Astragalus membranaceus selectively elevate adiponectin secretion from adipocytes and alleviate insulin resistance and glucose intolerance in obese mice. Provides the primary mechanistic basis for InnoSlim's adiponectin elevation and insulin-sensitivity claims. Animal/cellular study; human InnoSlim-specific efficacy data are not indexed in PubMed.
  3. Chao M, Zou D, Zhang Y, Chen Y, Wang M, Wu H, Ning G, Wang W Improving insulin resistance with traditional Chinese medicine in type 2 diabetic patients. Endocrine. 2009;36(2):268-74. doi: 10.1007/s12020-009-9222-y.PubMedUsed to support: Human clinical study showing Astragalus membranaceus-containing TCM formulas improved insulin resistance in type 2 diabetic patients. Supports glucose management and insulin-sensitivity benefits attributed to the Astragalus component of InnoSlim® at the compound level (not InnoSlim® brand-specific).